HIV Vaccine Achieves Breakthrough in Preclinical Study
Scientists at the La Jolla Institute for Immunology and Scripps Research have developed a new HIV vaccine that successfully triggers broadly neutralizing antibodies in primates. The vaccine, which has now entered human trials, represents a significant advancement in the 14-year effort to combat the virus.
Why it matters
This breakthrough could provide a long-sought solution for preventing HIV infection and AIDS, potentially saving millions of lives globally.
Scientists at La Jolla Institute for Immunology and Scripps Research have developed an HIV vaccine that trains immune cells to see past HIV's defenses.
The article reports on scientific research findings in a factual, objective manner without political or social commentary.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in